Modeling HCV kinetics under therapy using PK and PD information (Q56935271)

Expert Opinion on Drug Metabolism & Toxicology

Europe PubMed Central

title

Modeling HCV kinetics under therapy using PK and PD information (English)

0 references

Ruy M Ribeiro

2

0 references

Alan S. Perelson

series ordinal

3

object named as

Alan S Perelson

0 references

Emi Shudo

series ordinal

1

object named as

Emi Shudo

0 references

language of work or name

English

0 references

publication date

March 2009

0 references

published in

0 references

volume

5

0 references

page(s)

321-32

0 references

issue

3

0 references

cites work

Specific detection of hepatitis C virus minus strand RNA in hematopoietic cells

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Extrahepatic disease manifestations of HCV infection: some current issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Pegylation: a novel process for modifying pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Diagnosis, management, and treatment of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Modelling viral and immune system dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Treatment predictors of a sustained virologic response in hepatitis B and C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Modelling hepatitis C virus kinetics during treatment with pegylated interferon α-2b: errors in the estimation of viral kinetic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Modelling the kinetics of hepatitis C virus RNA decline over 4 weeks of treatment with pegylated interferon α-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Effect of ribavirin and amantadine on early hepatitis C virus RNA rebound and clearance in serum during daily high-dose interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Kinetics of pharmacologic response I. Proposed relationships between response and drug concentration in the intact animal and man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis C patients: a case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Modeling hepatitis C virus dynamics: Liver regeneration and critical drug efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Triphasic decline of hepatitis C virus RNA during antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Mathematical modeling of HCV infection and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Modeling complex decay profiles of hepatitis B virus during antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

HIV-1 infection and low steady state viral loads.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Effect of alpha interferon on the hepatitis C virus replicon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Mechanism of the interferon alpha response against hepatitis C virus replicons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

Cytopathic and Noncytopathic Interferon Responses in Cells Expressing Hepatitis C Virus Subgenomic Replicons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902787616

A hepatitis C viral kinetic model that allows for time-varying drug effectiveness.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2872514

Dynamic evolution of therapy for chronic hepatitis C: how will novel agents be incorporated into the standard of care?

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2872514

Influence of extrahepatic viral infection on the natural history of hepatitis C.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2872514

Noncompartmental vs. compartmental analysis: some bases for choice.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2872514

Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1

2 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19331594